The invention provides a process for manufacturing softgel capsules incorporating within said capsule one or more flat round tablets, said process comprising: (i) loading said flat round tablets into a tablet hopper; (ii) feeding said flat round tablets in a vertical orientation into guide channels; (iii) allowing said flat round tablets to move in the vertical orientation along the guide channels by the effect of gravity; (iv) allowing said flat round tablets to pass through a system incorporating a first retention piston and a second delivery piston; (v) allowing said flat round tablets to enter a distributor plate and wedge segment system through the top feed holes in said distributor plate; and (vi) incorporating said flat round tablets into the interior of the softgel capsule.
A61J 3/07 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
A61J 3/06 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
A23P 10/30 - Encapsulation of particles, e.g. foodstuff additives
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
2.
ENZYMATICALLY SYNTHESIZED OMEGA-3 AND OMEGA-6 STRUCTURED POLAR LIPIDS
The invention provides a process of incorporation of omega- 3 fatty acids such as EPA/DHA into polar lipid molecules present in lecithin, which consists of: (a) an enzymatic exchange reaction between the fatty acids present in the polar lipids of lecithin and the omega-3 fatty acids present in concentrated fish oil, to obtain an oil with a high content of polar lipids and omega-3 fatty acids and (b) a stage of concentration of the polar lipid content of the oil obtained in stage a, by supercritical fractionation or molecular distillation.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
The invention provides a process of incorporation of omega-3 fatty acids such as EPA/DHA into polar lipid molecules present in lecithin, which consists of: (a) an enzymatic exchange reaction between the fatty acids present in the polar lipids of lecithin and the omega-3 fatty acids present in concentrated fish oil, to obtain an oil with a high content of polar lipids and omega-3 fatty acids and (b) a stage of concentration of the polar lipid content of the oil obtained in stage a, by supercritical fractionation or molecular distillation.
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
4.
PRE-FILLING SYSTEM TO ELIMINATE BUBBLES INSIDE CAPSULES HAVING A SOLID DOSAGE FORM
The invention provides a rotary die mold process for manufacturing softgel capsules incorporating another solid form within said capsule and wherein said softgel capsule is free of air bubbles, in which at least two material strips are brought together by means of counter-running forming rolls and formed into capsules, a liquid and solid filling material being introduced via a filling wedge segment comprising two concave wedge surfaces; a filling medicine inlet; a fill medicine outlet; an output of solids and pre-fill medicine; a solids feed channel and pre-fill medicine; a pre-filling medicine inlet and a solids inlet. A softgel capsule free of air bubbles having incorporated within said capsule a second solid form, said second solid form being the form of a tablet.
A61J 3/07 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
A61K 9/54 - Sustained or differential release type containing discrete particles with coatings of different thicknesses or different materials
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 45/08 - Mixtures of an active ingredient and an auxiliary substance neither being chemically characterised, e.g. antihistaminicum and surface active substance
5.
PRE-FILLING SYSTEM TO ELIMINATE BUBBLES INSIDE CAPSULES HAVING A SOLID DOSAGE FORM
The invention provides a rotary die mold process for manufacturing softgel capsules incorporating another solid form within said capsule and wherein said softgel capsule is free of air bubbles, in which at least two material strips are brought together by means of counter-running forming rolls and formed into capsules, a liquid and solid filling material being introduced via a filling wedge segment comprising two concave wedge surfaces; a filling medicine inlet; a fill medicine outlet; an output of solids and pre-fill medicine; a solids feed channel and pre-fill medicine; a pre-filling medicine inlet and a solids inlet. A softgel capsule free of air bubbles having incorporated within said capsule a second solid form, said second solid form being the form of a tablet.
A61J 3/07 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
A61K 9/54 - Sustained or differential release type containing discrete particles with coatings of different thicknesses or different materials
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 45/08 - Mixtures of an active ingredient and an auxiliary substance neither being chemically characterised, e.g. antihistaminicum and surface active substance
A softgel capsule having incorporated within said capsule: (i) an active pharmaceutical ingredient in a liquid carrier exhibiting release profiles selected from the group consisting of immediate release, extended release and combinations thereof; and (ii) one or more smaller capsules or smaller solid dosage forms wherein said smaller capsules or smaller solid dosage forms have active ingredients that are compatible or not compatible with each other or with another active within the softgel capsule and wherein said smaller capsules or smaller solid dosage forms exhibit release profiles selected from the group consisting of extended release, and immediate release and combinations thereof.
A61K 9/54 - Sustained or differential release type containing discrete particles with coatings of different thicknesses or different materials
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 45/08 - Mixtures of an active ingredient and an auxiliary substance neither being chemically characterised, e.g. antihistaminicum and surface active substance
A softgel capsule having incorporated within said capsule: (i) an active pharmaceutical ingredient in a liquid carrier exhibiting release profiles selected from the group consisting of immediate release, extended release and combinations thereof; and (ii) one or more smaller capsules or smaller solid dosage forms wherein said smaller capsules or smaller solid dosage forms have active ingredients that are compatible or not compatible with each other or with another active within the softgel capsule and wherein said smaller capsules or smaller solid dosage forms exhibit release profiles selected from the group consisting of extended release, and immediate release and combinations thereof.
A61K 9/54 - Sustained or differential release type containing discrete particles with coatings of different thicknesses or different materials
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 45/08 - Mixtures of an active ingredient and an auxiliary substance neither being chemically characterised, e.g. antihistaminicum and surface active substance
patents
